Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook
Jefferies reduced its price target for Phathom Pharmaceuticals (NASDAQ:PHAT) to $16 from $20, citing a challenging year but a favorable 2027 outlook. The stock has fallen 58% year-to-date. Phathom reported Q2 2026 revenue of $74.27 million, up 88% YoY, but adjusted its full-year revenue guidance downward due to logistical issues. Analysts remain bullish, with H.C. Wainwright and Guggenheim maintaining Buy ratings.
How this was made
The 30-second read
Why it matters
The price‑target reduction reflects concerns over guidance and market perception, likely prompting short‑term downside despite Q2 beat.
Market read
Analyst target changes and Q2 results provide fresh data for traders; the net effect is modest downside pressure on PHAT.
What to watch
Potential upside from upcoming PCAB PDUFA decision in 2027 and expanding sales force may drive future growth.
Background
Phathom Pharmaceuticals (NASDAQ:PHAT) is a micro‑cap biotech focused on gastro‑esophageal therapies. Recent analyst coverage includes Jefferies, H.C. Wainwright, and Guggenheim.
Ticker impact
Jefferies lowered its price target for Phathom Pharmaceuticals to $16 from $20 and highlighted Q2 revenue growth and adjusted full-year guidance.
likely pressure as the market prices in the lower price target and guidance downgrade
Analyst downgrade is a fresh catalyst that can prompt short‑term sell‑offs.
Market effects
Biotech sector may see modest pullback as analysts reassess valuation multiples for small‑cap pharma peers.
US biotech investors may adjust exposure to early‑stage drug developers.
Limited to US‑listed micro‑cap pharma space.
Counterpoint
The strong Q2 revenue beat and operational profitability could outweigh the modest target cut, offering a buying opportunity.
Key entities
- AnalystJefferies
Lowered PHAT price target to $16.
- AnalystH.C. Wainwright
Maintained Buy rating with $26 target.
- AnalystGuggenheim
Reduced target to $22.
